Real World Health Care Blog

Tag Archives: therapeutic

Toys “R” Us Guide Makes the Season Brighter for Children with Special Needs

As we enter the holiday season, shoppers have the opportunity to turn to the Toy Guide for Differently-Abled Kids – an annual publication put out by Toys “R” Us. This valuable resource is designed to give parents, relatives, friends and professionals the information they need to make more educated choices about purchasing gifts for children with unique talents and abilities.

Paul DeMiglio

Paul DeMiglio

Gabby Douglas, a gold-medalist gymnast in the 2012 Olympics, is featured on this year’s edition and says the guide is “filled with everyday playthings, specially chosen to help kids build key skills, like creativity, language and critical thinking, reach new milestones and have fun at the same time.” Douglas is the most recent in a long line of celebrities and philanthropists who have appeared on the guide’s front cover, including Whoopi Goldberg, Eva Longoria and Maria Shriver.

“We understand the joy of watching a child experience victories through the magic of play, whether they’re learning to catch and throw a ball, role-playing through dress-up or learning to count using an app on their very first tablet,” said Kerry Smith, Toys “R” Us spokesperson. “For nearly two decades, we have been providing parents and caregivers with product recommendations for children with special needs through the trusted Toys“R”Us Toy Guide for Differently-Abled Kids. This annual resource is filled with everyday playthings selected as appropriate in helping kids build critical skills and reach new milestones – all while having fun at the same time.”

The guide provides shoppers with specific questions to help ensure that their selections match the developmental needs of the children for whom they’re shopping. Customers are encouraged to consider whether the toy fosters creativity and self-expression, if it provides a challenge without being frustrating, if it allows for adaptability to the child’s needs, whether the toy reflects the child’s interests and age, and much more.

The guide also shares numerous safety suggestions for parents and guardians so they can more effectively prevent accidental injuries and help children understand how to keep out of harm’s way during playtime:

  • Never leave a child unsupervised
  • Read labels for ability
  • Survey the play area
  • Establish concrete rules
  • Use visual warnings
  • Review and repeat
  • Prepare for off-site play dates
  • Click here for the full list

The toys were evaluated and tested by the National Lekotek Center, a non-profit that examines toys’ therapeutic qualities in aiding the development of children with physical, cognitive or developmental disabilities. A leader in the field with almost 30 years’ experience, Lekotek studies and reviews hundreds of toys, selecting those that benefit children. This information is then sent to Toys “R” Us for placement in the guide. Toys are categorized according to various child development needs such as visual, auditory, social skills and motor skills, among others.

If you would like to know more about the guide and the company’s philanthropic events, visit the new Toy Channel on YouTube, which includes an “‘R’ News” section that features information about charitable contributions. The guide can be found in any Toys “R” Us store or can be viewed online here.

Have you or someone you know ever used the Toy Guide for Differently-Abled Kids? Did it address your questions and make toy shopping for children with special needs easier? What challenges have you faced when purchasing toys for children with special needs, and what resources have you found helpful when making decisions?

Categories: Access to Care

Patient Venture Philanthropies: Catalyzing the Development and Delivery of Therapeutic Breakthroughs

Linda Barlow

Linda Barlow

How are patient-focused organizations making tangible advances in creating life-saving and life-enhancing therapeutic innovations? The experiences of at least two foundations show that collaboration with stakeholders across industries – private, government, academia, insurers and clinicians – is a good place to start.

One example of success is JDRF (formerly the Juvenile Diabetes Research Foundation), the only global organization with a strategic plan to systematically eradicate the effects of type 1 diabetes (T1D) from people’s lives. As a foundation with cure, treatment and prevention strategies that drive the core of its mission, JDRF funds $530 million in scientific research across 17 countries. JDRF’s highest priority is funding research to deliver a cure for T1D and its complications. It is also committed to:

  • Developing better treatments that will transform the way people of all ages with T1D treat the disease at any stage, in order to help them live healthier lives; and
  • Preventing T1D, to keep future generations from developing the disease.

JDRF focuses its funding on therapies and devices that are truly impactful, either in the sense of bringing something to market more quickly or by reaching the largest possible number of patients.

“The challenge is bigger than we anticipated,” according to Jeffrey Brewer, President & CEO of JDRF. “We remain committed to a cure, but are also focused on helping patients live safely and well until a cure comes, through preventive and treatment strategies and treatments.”

Brewer says that JDRF has started working more with industry, noting that historically, the organization focused on academic-based research.

“Forty years of advances in the academic labs has given us the opportunity to translate developments in the labs to companies that will develop therapies to deliver to people,” he says. “Academic research is a critical early component in the pipeline, but company support is also a critical part of the pipeline. That’s why we incentivize companies to do things they otherwise wouldn’t have done.”

“JDRF is willing to take on more risk at an early stage than pharmaceutical companies,” adds Dr. Richard A. Insel, M.D., Chief Scientific Officer, JDRF. “We also are not driven by profit margins or market size. We act as a sort of virtual pharma or biotech company in the early stages of research, and our industry partners step in to bring therapies and devices to market.”

Brewer explains that once companies are able to successfully commercialize therapies and see a financial return, JDRF is “paid back” by those companies, with funds JDRF drives back into more therapeutic research.

“We also work closely with our industry partners and the government, particularly the National Institutes for Health, to make sure resources are being used most effectively and without duplication of effort,” says Insel. “And we work with regulatory agencies to help them better understand what it is like to live with type 1 diabetes so they can evaluate the risk and benefits of new therapies with an eye toward approving them as quickly as possible.”

The Alzheimer’s Drug Discovery Foundation (ADDF) also focuses on prevention, treatment and cure. Using a venture philanthropy model to bridge the worldwide funding gap between basic research and later-stage drug development, ADDF leverages any return on investment to support new research.

The result? ADDF has granted more than $60 million to fund over 400 Alzheimer’s drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries.

“Our biomedical venture philanthropy model adapts the operating principles of venture capital investing to the ADDF’s philanthropic mission to advance biomedical research in Alzheimer’s disease. We seek a return on investment for our grants based on the achievement of scientific and/or business milestones. When these milestones are met, funds come back to the Foundation to increase our ability to fund more research,” according to the Foundation.

Source: Parkinsons Action Network

Source: Parkinson’s Action Network

Dr. Insel argues that the participation of patients and families in clinical trials is crucial to translating funding research into impactful therapies.

Do you agree? What other ways can patients living with type 1 diabetes, Alzheimer’s disease or other chronic disease act as advocates for themselves and the disease in general? What other patient venture philanthropy models have you seen work?